The Basel-based biopharmaceutical company, Okairos AG, specializes in the discovery and development of genetic T-cell vaccines for infectious diseases and cancer, including hepatitis C virus, malaria, HIV, Ebola and Marburg, and universal influenza. In addition to its vaccine development, the company also provides health and allied services. With operations in Rome and Naples, Italy, Okairos AG was formerly a subsidiary of Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa.